Image source: Shutterstock

Highlights

  • Avant Technologies and Ainnova Tech are in the final stages of prototyping a low-cost automated retinal camera.
  • The device will integrate with Ainnova’s Vision AI platform to generate diagnostic risk reports within seconds
  • The joint venture, Ai-nova Acquisition Corp., holds exclusive global rights to commercialize the technology

Avant Technologies Inc. is a U.S.-based emerging technology company developing artificial intelligence solutions for various sectors, including healthcare. Listed on the OTCQB under the ticker AVAI, the company focuses on applying AI and machine learning technologies to improve operational efficiency and innovation across multiple domains.

The company and its joint venture partner Ainnova Tech, Inc. announced that they are nearing completion of a prototype for a proprietary automated retinal camera. This development forms part of their efforts to make early disease detection using artificial intelligence (AI) more accessible and cost-efficient. The camera is being developed under their joint venture, Ai-nova Acquisition Corp. (AAC), which holds the global licensing rights to Ainnova’s health technology portfolio.

The new device aims to address one of the longstanding entry barriers in retinal imaging—the high cost of fundus cameras. According to Vinicio Vargas, CEO of Ainnova and board member of Ai-nova Acquisition Corp., the camera is expected to be significantly more affordable than existing alternatives. It is designed to automatically capture retinal images and upload them to the Vision AI software platform, which then generates a disease risk report in seconds.

The upcoming device will be packaged with Ainnova’s Vision AI software, which applies machine learning algorithms to retinal imaging data for early identification of disease markers. This integration is intended to streamline clinical workflows by providing rapid assessments that can support referrals to specialists in a timely manner. Beyond diabetic retinopathy, Vision AI is capable of detecting glaucoma, macular edema, age-related macular degeneration, and other ocular and systemic conditions. The software is also designed to assess health risks unrelated to retinal images by incorporating other patient data to identify markers of cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease.

Currently, the Vision AI platform is compatible with a range of fundus cameras already on the market. However, Avant and Ainnova’s aim is to develop an integrated solution that combines proprietary hardware with software, offering exclusivity and potentially differentiating it in the broader diagnostic market.

In addition to affordability and integration, the device is being developed with ease of use in mind, potentially expanding access to preventive screening tools across a wider range of healthcare providers. The goal, according to Vargas, is not only to support diabetic patients but also to broaden the use case to others at risk of chronic diseases, thereby advancing more comprehensive preventive care.

The joint venture, Ai-nova Acquisition Corp., is tasked with overseeing the development, maintenance, and commercialization of Ainnova’s technology portfolio. As part of the licensing agreement, AAC holds exclusive rights to globally market and develop the new retinal camera and related AI-driven software solutions. As the retinal camera prototype approaches completion, both companies are preparing for the next phase of validation and eventual deployment, aiming to expand diagnostic capabilities in healthcare settings with accessible AI-driven tools.